Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $2.3 million.

  • Vanda Pharmaceuticals' Share-based Compensation fell 2018.86% to $2.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.5 million, marking a year-over-year decrease of 2379.34%. This contributed to the annual value of $9.5 million for FY2025, which is 2379.34% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Share-based Compensation stood at $2.3 million for Q4 2025, which was down 2018.86% from $2.1 million recorded in Q3 2025.
  • Vanda Pharmaceuticals' Share-based Compensation's 5-year high stood at $4.8 million during Q1 2022, with a 5-year trough of $2.1 million in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' median Share-based Compensation value was $3.4 million (recorded in 2023), while the average stood at $3.4 million.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Share-based Compensation surged by 2602.87% in 2021 and then tumbled by 2957.65% in 2025.
  • Vanda Pharmaceuticals' Share-based Compensation (Quarter) stood at $3.8 million in 2021, then increased by 0.24% to $3.8 million in 2022, then decreased by 13.48% to $3.3 million in 2023, then fell by 12.53% to $2.9 million in 2024, then decreased by 20.19% to $2.3 million in 2025.
  • Its Share-based Compensation stands at $2.3 million for Q4 2025, versus $2.1 million for Q3 2025 and $2.1 million for Q2 2025.